Pradaxa antidote data lets Boehringer 'keep up' in oral anticoagulant race
This article was originally published in Scrip
Boehringer Ingelheim has presented the first clinical data for its antidote to Pradaxa (dabigatran), which could boost sales of the new anticoagulant treatment for patients with atrial fibrillation. With competitors Eliquis and Xarelto being tested in Phase II with Portola Pharmaceuticals' 'universal antidote', the positive data will come as a relief to Boehringer.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.